Patents Assigned to Vanda Pharmaceutical, Inc.
  • Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype
    Patent number: 9243295
    Abstract: The present invention relates to the treatment of an individual with an antipsychotic based on individual's genotype at one or more single nucleotide polymorphism (SNP) associated with the dopamine receptor D2 (DRD2) and/or ankyrin repeat and kinase domain containing 1 (ANKK1) genes.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: January 26, 2016
    Assignee: Vanda Pharmaceutical, Inc.
    Inventors: Christian Lavedan, Simona Volpi